Prognostic implications of combining <scp>EGFR‐TKIs</scp> and radiotherapy in Stage <scp>IV</scp> lung adenocarcinoma with <scp>19‐Del</scp> or <scp>21‐L858R</scp> mutations: A <scp>real‐world</scp> study

Shuai Liang, Hanyu Wang, Yingyun Zhang, Haixia Tian, Chengming Li, Dong HuaCancer 2024 · DOI

TL;DR

This real-world study investigated the combined efficacy of EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma patients with specific EGFR mutations (19-Del or 21-L858R). The findings suggest that combining these treatments leads to a significantly improved overall survival, particularly for patients with the 19-Del mutation, highlighting a potential personalized treatment strategy.

What Problem Does This Paper Address?

Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality globally, with a significant proportion of advanced cases diagnosed when surgical intervention is no longer feasible. For patients with non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) mutations, particularly exon 19 deletion (19-Del) or exon 21 L858R mutation (21-L858R), targeted therapy with EGFR-TKIs has become a cornerstone of treatment. However, brain and bone metastases are common challenges that contribute to treatment failure. While radiotherapy is often used to manage these metastases and alleviate symptoms, its synergistic effect with EGFR-TKIs, especially in relation to specific EGFR mutation subtypes, has not been fully elucidated in real-world settings. This study aims to address this gap by evaluating the prognostic implications of combining EGFR-TKIs with radiotherapy in a cohort of Stage IV LUAD patients with these common EGFR mutations.

Methods

This study employed a real-world, retrospective design. The researchers analyzed data from 177 patients diagnosed with clinical Stage IV LUAD who received both EGFR-TKIs and radiotherapy at Shandong Cancer Hospital between June 2012 and August 2017. The primary endpoint of the study was overall survival (OS).

Key methodological aspects include:

  • Patient Selection: Inclusion criteria were stringent, requiring patients to be at least 18 years old, have a Karnofsky performance status of ≥70, confirmed LUAD with 19-Del or 21-L858R mutations, and evidence of brain and/or bone metastasis. Patients also needed to have received EGFR-TKIs (first or second-line) and radiotherapy for symptomatic metastatic lesions or residual primary lesions.
  • Treatment Regimens: EGFR-TKIs included first-generation agents (gefitinib, erlotinib, icotinib) and, in some cases, osimertinib. Radiotherapy regimens encompassed thoracic conventional fractionation radiotherapy, whole-brain radiotherapy (WBRT), or boost radiotherapy for brain metastases, and palliative radiotherapy for bone metastases. Doses and fractions were standardized according to established guidelines.
  • Statistical Analysis: Clinical characteristics between the 19-Del and 21-L858R groups were compared using the chi-square test. Cox regression models were used to evaluate hazard ratios and confidence intervals for OS. Survival data were analyzed using the Kaplan-Meier method, with log-rank tests employed for comparisons.

Datasets

The study utilized a dataset of 177 patients with Stage IV LUAD from Shandong Cancer Hospital. This dataset represents a real-world cohort and is not a newly introduced benchmark. The data collected included patient demographics, clinical characteristics, treatment details (EGFR-TKIs, radiotherapy types), and survival outcomes.

Key Insights and Ideas

  • EGFR Mutation Subtypes Matter: While the clinical characteristics of patients with 19-Del and 21-L858R mutations were similar, their response to combined therapy differed significantly. This suggests that these mutations, despite being common, may represent distinct biological entities with varying sensitivities to treatment.
  • Radiotherapy's Crucial Role: The study strongly emphasizes the independent prognostic value of thoracic radiotherapy for OS, even when combined with EGFR-TKIs. This highlights that radiotherapy is not merely a palliative measure but an active component in improving survival outcomes.
  • Synergy with 19-Del: The most striking insight is the notably prolonged OS observed in patients with the 19-Del mutation who received combined EGFR-TKI and radiotherapy therapy, especially when compared to those with the 21-L858R mutation. This suggests a potential for more tailored treatment strategies based on specific EGFR mutation profiles.
  • Site-Specific Radiotherapy Differences: While thoracic radiotherapy showed a clear benefit, the impact of radiotherapy for brain metastases was less pronounced in this study. This could be due to factors like the blood-brain barrier penetration of EGFR-TKIs or the specific indications for brain radiotherapy in this advanced-stage cohort.

Key Results

  • Overall Survival: The overall median OS for all patients was 32.0 months.
  • Independent Predictors of OS: Multivariate analysis identified both EGFR mutations (19-Del vs. 21-L858R) and thoracic radiotherapy as independent predictors of OS.
  • 19-Del vs. 21-L858R: Patients with the 19-Del mutation experienced a significantly longer OS than those with the 21-L858R mutation (median OS: 35.7 vs. 25.1 months, p=0.0004).
  • Thoracic Radiotherapy Benefit: Patients receiving thoracic radiotherapy had a significantly improved OS compared to those who did not (median OS: 36.6 vs. 27.6 months, p=0.0058).
  • Subgroup Analysis (19-Del vs. 21-L858R):
    • Combined therapy with bone metastasis radiotherapy: 19-Del group had longer OS (34.7 vs. 25.1 months, p=0.0056).
  • Combined therapy with thoracic radiotherapy: 19-Del group had longer OS (51.0 vs. 29.6 months, p=0.0013).
  • Combined therapy with brain metastasis radiotherapy: No significant difference in OS was observed (34.7 vs. 25.1 months, p=0.088).
  • Tolerability: The combined therapy was generally well-tolerated, with common side effects including skin rash, radiation-induced brain injury, pneumonia, neutropenia, fatigue, anorexia, nausea, and vomiting. No severe (G3 or G4) toxicities were reported.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective and Single-Center Design: This limits the generalizability of the findings and introduces potential selection bias.
  • Lack of EGFR-TKI Type Investigation: The study did not specifically investigate the differential effects of various EGFR-TKI types on OS.
  • Limited Investigation of Multisite Radiotherapy: The research did not extensively explore the impact of various treatment modalities and multisite radiotherapy on OS outcomes.

Future work suggested by the authors includes:

  • Prospective Trials: The need for more substantial evidence from various current prospective trials (e.g., NCT02788058, NCT00973310, NCT03727867, NCT02893332) to further validate the efficacy of combining radiotherapy and EGFR-TKIs.
  • Investigating Blood-Brain Barrier Penetration: Further research is needed to account for the varying blood-brain barrier-crossing efficacy of different EGFR-TKIs, especially concerning brain metastasis.
  • Exploring Underlying Mechanisms: Deeper investigation into the complex interactions between radiotherapy and targeted therapy, including tumor radiosensitivity, oxygenation, cell cycle redistribution, and neovascularization suppression, could provide further insights.

Summary updated

Abstract

Patients with Stage IV LUAD harboring 19-Del experience a notably prolonged OS following combined therapy with EGFR-TKIs and radiotherapy, while this OS benefit is observed despite the absence of substantial differences in the clinical characteristics between the 19-Del and 21-L858R groups.
BibTeX
@inproceedings{liang2024prognostic,
  author = {Shuai Liang and Hanyu Wang and Yingyun Zhang and Haixia Tian and Chengming Li and Dong Hua},
  title = {{Prognostic implications of combining <scp>EGFR‐TKIs</scp> and radiotherapy in Stage <scp>IV</scp> lung adenocarcinoma with <scp>19‐Del</scp> or <scp>21‐L858R</scp> mutations: A <scp>real‐world</scp> study}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.7208},
}
Figure